Neuland Laboratories Share Price Target 2026, 2027, 2028, 2029, 2030
- Market Cap
- ₹24,808 Cr
- Book Value
- ₹1,461
- Stock P/E
- 68.7
- Dividend Yield
- 0.18%
- ROE
- 21.3%
- ROCE
- 26.5%
- PEG Ratio
- 1.78
- EV/EBITDA
- 41.1
Fundamentals from Screener.in, as of 5 Aug 2026. Live price via Yahoo Finance.
Technical snapshot
EOD ·Neuland Laboratories Ltd closed at ₹23,290.00 on 19 August 2026, down 0.3% on the day, 20.1% above its 50-day average, 2.5% below its 52-week high, with volume at 0.30× its 20-session average.
- RSI 14
- 69.8
- vs 50-day SMA
- +20.1%
- vs 200-day SMA
- +44.7%
- From 52-week high
- -2.5%
- Relative volume
- 0.30×
- 20-day return
- +26.1%
End-of-day prices from exchange-published files (NSE/BSE bhavcopy), updated after market close. Descriptive statistics, not investment advice.
Neuland Laboratories share price today
Neuland Laboratories (NSE: NEULANDLAB) climbed pharma’s value chain the patient way: three decades of API manufacturing discipline, then a decisive pivot into CMS — custom manufacturing for innovators — where it now makes complex molecules (and increasingly peptides, the chemistry behind the GLP-1 era) for global drug companies from clinical phases through commercial launch. When an innovator’s molecule wins, Neuland’s contracted volumes win with it.
The P&L shows the mix shifting: 28.7% operating margins (unrecognisable from its generic-API past), 38.5% five-year profit CAGR, ROCE past 26%. At 68.7×, the valuation already assumes continued CMS conversion despite a 2.29% promoter pledge and the client concentration inherent to that business.
The innovator’s contract shop
CMS produces milestone-linked development revenue and can become recurring commercial-supply revenue when a client molecule succeeds. Switching is constrained by regulatory filings that name Neuland’s plants. The peptide capability is the timely kicker: GLP-1-class molecules need exactly this chemistry at exactly this scale-up quality, and qualified capacity is globally scarce. The legacy API book (deuterated compounds, niche generics) funds the pipeline while CMS compounds.
What matters next: CMS client concentration (a few molecules can dominate), the 2.29% promoter pledge, commercial-launch timing of pipeline molecules (binary quarters), and capacity-expansion execution.
The numbers
Financial snapshot — 5 August 2026
| Metric | Value |
|---|---|
| Market cap | ₹24,808 Cr |
| P/E (TTM) | 68.7 |
| EV/EBITDA | 41.1 |
| Operating margin | 28.7% |
| ROE / ROCE | 21.3% / 26.5% |
| Debt to equity | 0.16 |
| Sales CAGR (5y) | 16.6% |
| Profit CAGR (5y) | 38.5% |
| Promoter holding | 32.6% (2.29% pledged) |
| EPS (TTM) | ₹280.5 |
Neuland Laboratories share price target 2026 to 2030
EPS base ₹280.5 (TTM). Bear: a key molecule disappoints, growth normalises — 10% growth, multiple at 35×. Base: CMS pipeline converts steadily — 18% growth at 50×. Bull: peptide era scales through Neuland — 25% growth at 65×.
From ₹19,273, the base case is ≈ +66% over four and a half years; the bear is −18%. That spread reflects molecule-event risk: the platform can compound, but one client setback can reset both earnings and the multiple.
What supports the case
- CMS annuities: regulatory filings lock its plants into innovators’ supply chains.
- Peptide capability lands precisely on the GLP-1 decade’s scarcest input.
- Margin transformation (28.7% OPM) evidences the mix shift is real.
- 38.5% five-year profit CAGR with ROCE climbing past 26%.
- Three decades of FDA-inspected manufacturing credibility.
The risks: client/molecule concentration makes single events material, the promoter pledge (2.29%) is small but still worth monitoring, and 69× prices continued conversion success.
What to weigh at the current price
The tension is whether peptide and CMS scale quickly enough to justify 68.7× earnings before concentration or a delayed molecule exposes how much success is already priced in.
FAQ
What is the Neuland Laboratories share price target for 2030? The table above sets out bear, base and bull scenarios for each year to 2030. They are valuation sensitivities, not promised prices.
What is the CMS business? Custom Manufacturing Solutions — making innovators’ proprietary molecules under contract from clinical through commercial phases. Revenue scales with the client drug’s success and stays locked by regulatory filings.
Why do peptides matter now? GLP-1 obesity/diabetes drugs are peptide-based and supply-constrained globally. Qualified peptide API capacity — Neuland’s build-out — is among pharma’s scarcest assets this decade.
When are Neuland’s next results? Check the results calendar and confirm the announced date in the company’s exchange filing.
This article is research and education, not personalised investment advice. We are not SEBI-registered advisers. Price targets are scenario arithmetic, not promises. Do your own research and consult a registered adviser before acting.